SCHEMBL3451874

SCHEMBL3451874

Cc1ncc2n1C(=O)N(N1CCN(C(=O)C(NC(=O)Nc3ccc(Cl)cc3)C3CC3)CC1)C2

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
F10 P00742 5/20 0.47
F2 P00734 2/20 0.40
CCR1 P32246 1/20 0.38
NR3C1 P04150 8/20 0.37
RAB9A P51151 2/20 0.36
FPR2 P25090 2/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
KMT2A Q03164 1/20 0.35
RELA Q04206 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EPHX2 P34913 1/20 0.34
IDO1 P14902 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3449086 0.97 F10 (0.46) F10F2CCR1NR3C1RAB9A
SCHEMBL3449605 0.96 F10 (0.45) F10F2CCR1NR3C1RAB9A
SCHEMBL3448624 0.95 F10 (0.45) F10F2CCR1NR3C1RAB9A
SCHEMBL3451344 0.87 CCR1 (0.48) F10F2CCR1FPR2
SCHEMBL3450095 0.86 F10 (0.54) F10F2CCR1NR3C1RAB9A
SCHEMBL3450303 0.86 F10 (0.47) F10F2CCR1NR3C1RAB9A
SCHEMBL3449908 0.86 F10 (0.47) F10F2CCR1NR3C1RAB9A
SCHEMBL3452169 0.86 F10 (0.46) F10F2CCR1NR3C1RAB9A
SCHEMBL3449849 0.85 F10 (0.46) F10F2CCR1NR3C1RAB9A
SCHEMBL3449335 0.85 F10 (0.46) F10F2CCR1NR3C1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-7820673-B2 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
US-20070093501-A1 Urea derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-04-26 US disclosed
EP-1695961-A1 UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2006-08-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093501-A1 Urea derivative, process for producing the same, and use F2, URB2, F12 F10 22/4885F2 1/4885CCR1 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.